[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Schneider C, Wiendl H, Ogilvie A: Biphasic cytotoxic mechanism of extracellular ATP on U-937 human histiocytic leukemia cells: involvement of adenosine generation. Biochim Biophys Acta; 2001 Apr 23;1538(2-3):190-205
Hazardous Substances Data Bank. Adenosine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biphasic cytotoxic mechanism of extracellular ATP on U-937 human histiocytic leukemia cells: involvement of adenosine generation.
  • Since extracellular ATP can exhibit cytotoxic activity in vivo and in vitro, its application has been proposed as an alternative anticancer therapy.
  • Considering ATP as a potential cytostatic drug, our data have important implications concerning metabolic interactions of administered nucleotides.
  • [MeSH-minor] Apoptosis. Cell Differentiation / drug effects. Cell Division / drug effects. Dose-Response Relationship, Drug. Humans. Leukemia, Monocytic, Acute / metabolism. Microscopy, Phase-Contrast. Purinergic P1 Receptor Agonists. Purinergic P1 Receptor Antagonists. Pyrimidines / metabolism. Receptor, Adenosine A3. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11336790.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Purinergic P1 Receptor Agonists; 0 / Purinergic P1 Receptor Antagonists; 0 / Pyrimidines; 0 / Receptor, Adenosine A3; 8L70Q75FXE / Adenosine Triphosphate; K72T3FS567 / Adenosine; K8CXK5Q32L / pyrimidine
  •  go-up   go-down


2. Hull DR, Alexander HD, Markey GM, Lyness RW, Morris TC: Histiocytic lymphoma presenting as a testicular tumour and terminating in acute monoblastic leukaemia. J Clin Pathol; 2000 Oct;53(10):788-90
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histiocytic lymphoma presenting as a testicular tumour and terminating in acute monoblastic leukaemia.
  • Six months later he developed a buccal lesion, which was biopsied and reported as a high grade non-Hodgkin's lymphoma.
  • It responded completely to chemotherapy but within a year he developed a forearm swelling, which was biopsied and imprints made before fixation of the material.
  • Immunocytochemistry on the imprints showed positivity with antibodies to CD4, CD68, and muramidase, and the non-specific esterase cytochemical stain was strongly positive, leading to a diagnosis of true histiocytic lymphoma.
  • Despite further treatment, the patient entered a terminal acute leukaemic phase, the blasts marking as monoblasts.
  • Review of all the biopsies, including molecular investigations and further immunohistochemistry studies performed retrospectively on the original biopsy, demonstrated that this was the same malignant cell line throughout, and we conclude that this is a case of histiocytic lymphoma, initially presenting as a testicular tumour and terminating in acute monoblastic leukaemia.
  • A diagnosis of histiocytic lymphoma should be considered when lymphoid markers are negative in an apparent lymphoma, but should not be made without recourse to appropriate immunophenotypic and molecular studies.
  • [MeSH-major] Leukemia, Monocytic, Acute / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11064675.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Other-IDs] NLM/ PMC1731083
  •  go-up   go-down


3. Kong D, Aoki S, Sowa Y, Sakai T, Kobayashi M: Smenospongine, a sesquiterpene aminoquinone from a marine sponge, induces G1 arrest or apoptosis in different leukemia cells. Mar Drugs; 2008;6(3):480-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smenospongine, a sesquiterpene aminoquinone from a marine sponge, induces G1 arrest or apoptosis in different leukemia cells.
  • Smenospongine, a sesquiterpene aminoquinone isolated from the marine sponge Dactylospongia elegans, was previously reported by us to induce erythroid differentiation and G1 phase arrest of K562 chronic myelogenous leukemia cells.
  • In this study, we investigated the effect of smenospongine on the cell cycles of other leukemia cells, including HL60 human acute promyelocytic leukemia cells and U937 human histiocytic lymphoma cells by flow cytometric analysis.
  • The smenospongine treatment increased expression of p21 and inhibited phosphorylation of Rb in K562 cells, suggesting the p21-Rb pathway play an important role in G1 arrest in K562 cells.
  • However, the p21 promoter was not activated by the smenospongine treatment based on a luciferase assay using the transfected K562 cells.
  • [MeSH-major] Apoptosis / drug effects. G1 Phase / drug effects. Leukemia / drug therapy. Porifera / chemistry. Quinones / chemistry. Quinones / pharmacology. Sesquiterpenes / chemistry. Sesquiterpenes / pharmacology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Feb 1;105(3):959-67 [15466934.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4266-70 [10485470.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):121-32 [16949736.001]
  • [Cites] Stem Cells Dev. 2007 Jun;16(3):503-14 [17610380.001]
  • [Cites] J Manag Care Pharm. 2007 Oct;13(8 Suppl A):8-12 [17970609.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar 30;282(2):426-31 [11401476.001]
  • [Cites] Biochem Pharmacol. 2002 Oct 1;64(7):1079-90 [12234611.001]
  • [Cites] Curr Opin Hematol. 2004 Jan;11(1):35-43 [14676625.001]
  • [Cites] Anticancer Drugs. 2004 Apr;15(4):363-9 [15057141.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2004 Aug;52(8):935-7 [15304984.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2325-30 [15330179.001]
  • [Cites] Blood. 1975 Mar;45(3):321-34 [163658.001]
  • [Cites] Nature. 1982 Dec 23;300(5894):765-7 [6960256.001]
  • [Cites] Leukemia. 1992 Aug;6(8):839-42 [1640738.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Dec 8;241(1):142-50 [9405248.001]
  • [Cites] Cell Death Differ. 1998 Aug;5(8):710-5 [10200527.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 31;342(1):101-6 [16480688.001]
  • (PMID = 19005580.001).
  • [ISSN] 1660-3397
  • [Journal-full-title] Marine drugs
  • [ISO-abbreviation] Mar Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Quinones; 0 / Sesquiterpenes; 0 / smenospongine
  • [Other-IDs] NLM/ PMC2579737
  • [Keywords] NOTNLM ; G1 arrest / Rb / Smenospongine / apoptosis / leukemia cells / p21
  •  go-up   go-down


Advertisement
4. Castro EC, Blazquez C, Boyd J, Correa H, de Chadarevian JP, Felgar RE, Graf N, Levy N, Lowe EJ, Manning JT Jr, Proytcheva MA, Senger C, Shayan K, Sterba J, Werner A, Surti U, Jaffe R: Clinicopathologic features of histiocytic lesions following ALL, with a review of the literature. Pediatr Dev Pathol; 2010 May-Jun;13(3):225-37

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of histiocytic lesions following ALL, with a review of the literature.
  • We describe the clinicopathologic features of 15 patients who had histiocytic lesions that followed acute lymphoblastic leukemia (ALL).
  • Twenty-one separate histiocytic lesions were evaluated that covered a wide spectrum, some conforming to the usual categories of juvenile xanthogranulomas (5), Langerhans' cell histiocytosis (1), Langerhans' cell sarcoma (4), Rosai-Dorfman disease (1), and histiocytic sarcoma (4).
  • Seven low-grade lesions defied easy categorization and were characterized only as "atypical histiocytic lesion" following ALL.
  • For those evaluated, the molecular signature of the prior leukemia was present in the histiocytic lesion.
  • In 3 of 15 patients, the leukemia and histiocytic lesion shared immunoglobulin H or monoclonal TCR gene rearrangements and, in 4 of 15 patients, clonal identity was documented by fluorescence in situ hybridization.
  • Four patients died of progressive disease, 3 of whom had histiocytic sarcoma and 1 who had an atypical lesion.
  • The other 10 patients are alive, 7 after recurrences and treatment with surgery and/or chemotherapy.
  • The post-ALL lesions are more aggressive than their native counterparts, but despite the demonstration of the presence of the leukemia signature in 7 of 15 patients, the prognosis is generally favorable, except for patients with histiocytic sarcoma.
  • It remains unclear whether the histiocytic lesions arise as a line from the original ALL or whether transdifferentiation is involved.
  • [MeSH-major] Histiocytes / pathology. Histiocytosis / pathology. Neoplasms, Multiple Primary / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Aged. Child. Child, Preschool. Combined Modality Therapy. Female. Gene Rearrangement, B-Lymphocyte / genetics. Gene Rearrangement, beta-Chain T-Cell Antigen Receptor / genetics. Humans. Immunoglobulin Heavy Chains / genetics. In Situ Hybridization, Fluorescence. Male. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19642834.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  • [Number-of-references] 43
  •  go-up   go-down


5. Bergom C, Paddock C, Gao C, Holyst T, Newman DK, Newman PJ: An alternatively spliced isoform of PECAM-1 is expressed at high levels in human and murine tissues, and suggests a novel role for the C-terminus of PECAM-1 in cytoprotective signaling. J Cell Sci; 2008 Apr 15;121(Pt 8):1235-42
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An alternatively spliced isoform of PECAM-1 is expressed at high levels in human and murine tissues, and suggests a novel role for the C-terminus of PECAM-1 in cytoprotective signaling.
  • Using a novel rabbit polyclonal antibody that specifically recognizes Delta15 PECAM-1, we found that the Delta15 PECAM-1 isoform was expressed in human tissues, including brain, testes and ovary.
  • This isoform was also expressed on the cell surface of human platelets, human umbilical vein endothelial cells (HUVECs) and the Jurkat T-cell leukemia, human erythroleukemia (HEL) and U937 histiocytic lymphoma cell lines.
  • Delta15 PECAM-1 was unable, however, to protect against apoptosis induced by overexpression of Bax or treatment with the chemotherapy agent etoposide.
  • These studies suggest a novel role for the PECAM-1 C-terminus in cytoprotective signaling and highlight a need for further characterization of expression of PECAM-1 isoforms in normal and malignant tissues.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 1999 Feb 1;162(3):1376-83 [9973392.001]
  • [Cites] J Immunol. 1999 Mar 1;162(5):3022-30 [10072554.001]
  • [Cites] J Cell Sci. 1999 Jun;112 ( Pt 12):1989-97 [10343075.001]
  • [Cites] J Immunol. 1999 Jul 15;163(2):682-8 [10395658.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1319-29 [10438720.001]
  • [Cites] J Neurooncol. 1999 May;43(1):19-25 [10448867.001]
  • [Cites] J Immunol. 2004 Nov 15;173(10):6403-8 [15528380.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Jan;288(1):H159-64 [15319204.001]
  • [Cites] Am J Pathol. 2005 Jan;166(1):185-96 [15632011.001]
  • [Cites] J Biol Chem. 1992 Mar 15;267(8):5243-9 [1544907.001]
  • [Cites] J Exp Med. 1992 Jul 1;176(1):245-53 [1377224.001]
  • [Cites] J Exp Med. 1993 Aug 1;178(2):449-60 [8340753.001]
  • [Cites] Blood. 1993 Nov 1;82(9):2649-63 [7693043.001]
  • [Cites] Science. 1993 Dec 3;262(5139):1580-2 [8248808.001]
  • [Cites] J Exp Med. 1994 Mar 1;179(3):1059-64 [8113674.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2055-9 [8174104.001]
  • [Cites] J Biol Chem. 1994 Jun 24;269(25):17183-91 [8006026.001]
  • [Cites] Ann N Y Acad Sci. 1994 Apr 18;714:165-74 [8017765.001]
  • [Cites] Development. 1994 Sep;120(9):2539-53 [7956830.001]
  • [Cites] J Immunol. 1994 Nov 15;153(10):4673-83 [7525710.001]
  • [Cites] Blood. 1994 Dec 15;84(12):4028-37 [7994021.001]
  • [Cites] J Immunol. 1995 Jan 1;154(1):299-307 [7995949.001]
  • [Cites] Trends Cardiovasc Med. 2002 Jul;12(5):213-9 [12161075.001]
  • [Cites] J Cell Biochem. 2002;87(4):424-38 [12397602.001]
  • [Cites] J Exp Med. 2002 Nov 4;196(9):1201-11 [12417630.001]
  • [Cites] Blood. 2003 Jan 1;101(1):186-93 [12393747.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3169-77 [15632208.001]
  • [Cites] J Cell Biochem. 2005 Jun 1;95(3):559-70 [15786495.001]
  • [Cites] J Cell Sci. 2005 Oct 15;118(Pt 20):4865-77 [16219692.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2006 Jan;290(1):R57-65 [16166207.001]
  • [Cites] Blood. 2006 Jan 15;107(2):535-41 [16166583.001]
  • [Cites] Arch Pathol Lab Med. 2006 Apr;130(4):480-2 [16594742.001]
  • [Cites] Cancer Biol Ther. 2006 Dec;5(12):1699-707 [17106245.001]
  • [Cites] Blood. 2007 May 15;109(10):4237-44 [17234740.001]
  • [Cites] Blood. 2007 Aug 1;110(3):851-9 [17412889.001]
  • [Cites] Cell Adhes Commun. 1995 Feb;3(1):45-66 [7538415.001]
  • [Cites] J Leukoc Biol. 1999 Nov;66(5):698-704 [10577496.001]
  • [Cites] J Cell Sci. 2000 Apr;113 ( Pt 8):1459-69 [10725228.001]
  • [Cites] Mol Biol Cell. 2000 Aug;11(8):2793-802 [10930470.001]
  • [Cites] Tissue Antigens. 2000 Aug;56(2):105-16 [11019910.001]
  • [Cites] J Cell Biol. 2001 Jan 8;152(1):65-73 [11149921.001]
  • [Cites] Transplantation. 2001 Feb 15;71(3):457-60 [11233910.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1727-32 [11238114.001]
  • [Cites] J Immunol. 2001 Mar 1;166(5):3098-106 [11207261.001]
  • [Cites] FASEB J. 2001 May;15(7):1257-60 [11344106.001]
  • [Cites] Dev Biol. 2001 Jun 15;234(2):317-29 [11397002.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1456-63 [11520795.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 May;282(5):C1181-90 [11940533.001]
  • [Cites] Blood. 2002 Jul 1;100(1):184-93 [12070026.001]
  • [Cites] J Exp Med. 1989 Aug 1;170(2):399-414 [2666561.001]
  • [Cites] Science. 1990 Mar 9;247(4947):1219-22 [1690453.001]
  • [Cites] J Cell Biol. 1990 Apr;110(4):1227-37 [2182647.001]
  • [Cites] J Immunol. 1992 Jan 15;148(2):388-96 [1345920.001]
  • [Cites] Thromb Haemost. 1991 Oct 1;66(4):494-9 [1796401.001]
  • [Cites] Thromb Haemost. 1991 Dec 2;66(6):700-7 [1796415.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2003 Mar;284(3):H1008-17 [12433657.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2816-25 [12468430.001]
  • [Cites] FEBS Lett. 2003 Apr 10;540(1-3):7-14 [12681475.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Jun 1;23(6):953-64 [12689916.001]
  • [Cites] Blood. 2003 Jul 1;102(1):169-79 [12649141.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3658-64 [12893757.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2003 Dec;285(6):H2336-44 [12893640.001]
  • [Cites] Mol Vis. 2004 Feb 17;10:103-11 [14978479.001]
  • [Cites] J Biol Chem. 1995 Oct 6;270(40):23672-80 [7559536.001]
  • [Cites] J Exp Med. 1995 Nov 1;182(5):1337-43 [7595204.001]
  • [Cites] J Immunol. 1996 Feb 15;156(4):1515-24 [8568255.001]
  • [Cites] J Biol Chem. 1996 May 10;271(19):11090-8 [8626652.001]
  • [Cites] J Biol Chem. 1996 Aug 2;271(31):18561-70 [8702505.001]
  • [Cites] J Biol Chem. 1997 Mar 14;272(11):6986-93 [9054388.001]
  • [Cites] J Clin Invest. 1997 May 1;99(9):2139-51 [9151786.001]
  • [Cites] J Clin Invest. 1997 May 1;99(9):2152-64 [9151787.001]
  • [Cites] FEBS Lett. 1997 May 26;408(3):331-6 [9188788.001]
  • [Cites] Mol Biol Cell. 1997 Jul;8(7):1329-41 [9243511.001]
  • [Cites] J Biol Chem. 1997 Aug 15;272(33):20555-63 [9252369.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):671-7 [9284815.001]
  • [Cites] J Biol Chem. 1997 Oct 3;272(40):24868-75 [9312087.001]
  • [Cites] J Biol Chem. 1997 Dec 5;272(49):31086-91 [9388260.001]
  • [Cites] J Clin Invest. 1998 Jan 1;101(1):212-22 [9421484.001]
  • [Cites] Blood. 1998 Jan 15;91(2):500-7 [9427703.001]
  • [Cites] J Clin Invest. 1999 Jan;103(1):5-9 [9884328.001]
  • [Cites] Dev Dyn. 1999 Jan;214(1):44-54 [9915575.001]
  • (PMID = 18388311.001).
  • [ISSN] 0021-9533
  • [Journal-full-title] Journal of cell science
  • [ISO-abbreviation] J. Cell. Sci.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL040926-20; United States / NHLBI NIH HHS / HL / R01 HL040926; United States / NHLBI NIH HHS / HL / HL-40926; United States / NHLBI NIH HHS / HL / R01 HL040926-20
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / DNA Primers
  • [Other-IDs] NLM/ NIHMS71027; NLM/ PMC2567807
  •  go-up   go-down


6. Singh YP, Agarwal V, Krishnani N, Misra R: Enthesitis-related arthritis in Kikuchi-Fujimoto disease. Mod Rheumatol; 2008;18(5):492-5
MedlinePlus Health Information. consumer health - Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histiocytic necrotizing lymphadenitis or Kikuchi-Fujimoto disease (KFD) is a rare, benign and self-limiting disorder that characteristically presents with fever and cervical lymphadenopathy.
  • Work-up for infectious etiology, systemic lupus erythematosus and leukemia and lymphoma was negative.
  • Fever, lymphadenopathy and leukopenia dissipated with nonsteroidal anti inflammatory drug therapy, but the arthritis persisted.

  • Genetic Alliance. consumer health - Kikuchi disease.
  • Genetic Alliance. consumer health - Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18470474.001).
  • [ISSN] 1439-7595
  • [Journal-full-title] Modern rheumatology
  • [ISO-abbreviation] Mod Rheumatol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Suojanen J, Salo T, Sorsa T, Koivunen E: AlphaMbeta2 integrin modulator exerts antitumor activity in vivo. Anticancer Res; 2007 Nov-Dec;27(6B):3775-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Leukocyte immunomodulation has great clinical potential as a therapy of inflammatory conditions and cancer.
  • We have recently developed leukocyte alphaMbeta2 integrin targeting small molecule (IMB-10) capable of inhibiting leukocyte migration and recruitment in vitro and in vivo.
  • MATERIALS AND METHODS: The purpose of this study was to investigate the potential anticancer effects of IMB-10 using U937 histiocytic lymphoma, OCI-AML-3 acute myeloid leukemia and HSC-3 tongue squamous cell carcinoma xenografts in athymic nude mice lacking T-lymphocytes.
  • RESULTS: IMB-10 therapy inhibited the growth of both leukemia and lymphoma xenografts and significantly prolonged the survival of the mice with lymphoma.
  • CONCLUSION: IMB-10 has potential as a therapy for leukocytic malignancies, particularly for lymphomas.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Leukemia, Myeloid / drug therapy. Lymphocytes, Tumor-Infiltrating / drug effects. Macrophage-1 Antigen / immunology. Thiazoles / pharmacology. Tongue Neoplasms / drug therapy
  • [MeSH-minor] Acute Disease. Animals. Cell Growth Processes / drug effects. Cell Line, Tumor. Female. Gelatinases / metabolism. Humans. Mice. Mice, Nude. U937 Cells. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18225532.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / IMB 10; 0 / Macrophage-1 Antigen; 0 / Thiazoles; EC 3.4.24.- / Gelatinases
  •  go-up   go-down


8. Song SY, Ko YH, Ahn G: Mediastinal germ cell tumor associated with histiocytic sarcoma of spleen: case report of an unusual association. Int J Surg Pathol; 2005 Jul;13(3):299-303
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal germ cell tumor associated with histiocytic sarcoma of spleen: case report of an unusual association.
  • We present an unusual association of mediastinal germ cell tumor containing seminoma and angiosarcoma components and splenic histiocytic sarcoma.
  • An abdominal ultrasonogram revealed a huge splenomegaly with multiple ill-defined low echogenic nodules, 1 month after the second cycle of chemotherapy.
  • This lesion might have been on the pathway of multistep tumorigenesis toward a final leukemia.
  • [MeSH-major] Hemangiosarcoma / pathology. Histiocytic Sarcoma / pathology. Mediastinal Neoplasms / pathology. Seminoma / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Male. Neoplasms, Multiple Primary. Splenomegaly. Treatment Outcome

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086090.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


9. Kajiwara R, Goto H, Yanagimachi M, Kuroki F, Fujii H, Takahashi H, Yokota S: [Recurrent spontaneous regression of aleukemic leukemia cutis in a girl with acute monocytic leukemia]. Rinsho Ketsueki; 2006 Aug;47(8):764-9
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent spontaneous regression of aleukemic leukemia cutis in a girl with acute monocytic leukemia].
  • Aleukemic leukemia cutis is a rare form of leukemia manifestation, defined as a skin infiltration of leukemic cells with no evidence of leukemia in the bone marrow.
  • Histological examination revealed partial infiltration of histiocytic cells in the skin lesion.
  • However, the diagnosis could not be made at that time.
  • At 9 and at 13 months old, appearances of exanthema similar to the previous time were combined with systemic fever, abnormal coagulation tests, and the marked increases of atypical lymphocytes in peripheral blood: however, these symptoms resolved spontaneously.
  • Bone marrow aspiration revealed the predominance of monocytic blasts (76.4%), and the patient was diagnosed as having acute monocytic leukemia (M5b) with leukemia cutis.
  • Complete remission was obtained with standard chemotherapy.
  • Six months after the therapy was completed, an extramedullary relapse occurred in the inguinal lymph nodes, which was successfully treated with allogeneic bone marrow transplantation from an HLA-matched unrelated donor, and the patient has been free of disease for two years after the transplantation.
  • [MeSH-major] Leukemia / diagnosis. Leukemia / etiology. Leukemia, Monocytic, Acute / complications. Neoplasm Regression, Spontaneous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16986716.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Gerritsen A, Lam K, Marion Schneider E, van den Heuvel-Eibrink MM: An exclusive case of juvenile myelomonocytic leukemia in association with Kikuchi's disease and hemophagocytic lymphohistiocytosis and a review of the literature. Leuk Res; 2006 Oct;30(10):1299-303
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An exclusive case of juvenile myelomonocytic leukemia in association with Kikuchi's disease and hemophagocytic lymphohistiocytosis and a review of the literature.
  • We present a case of juvenile myelomonocytic leukemia (JMML) accompanied by immune-mediated hemophagocytic lymphohistiocytosis (HLH) and Kikuchi's disease, both as a paraneoplastic phenomenon.
  • As this combination, to the best of our knowledge, has not been described before, consensus on preferable treatment is lacking.
  • [MeSH-major] Histiocytic Necrotizing Lymphadenitis / complications. Leukemia, Myelomonocytic, Acute / complications. Lymphohistiocytosis, Hemophagocytic / complications. Lymphohistiocytosis, Hemophagocytic / drug therapy. Prednisolone / therapeutic use
  • [MeSH-minor] Humans. Infant. Male. Treatment Outcome


11. Ambati S, Chamyan G, Restrepo R, Escalon E, Fort J, Pefkarou A, Khatib ZA, Dehner LP: Rosai-Dorfman disease following bone marrow transplantation for pre-B cell acute lymphoblastic leukemia. Pediatr Blood Cancer; 2008 Sep;51(3):433-5
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rosai-Dorfman disease following bone marrow transplantation for pre-B cell acute lymphoblastic leukemia.
  • A child with acute pre-B cell lymphoblastic leukemia underwent haploidentical bone marrow transplantation (BMT) after first relapse.
  • Approximately 8 months after the BMT, he developed a soft tissue mass overlying a defect in the left frontal bone.
  • A biopsy of the presenting lesion demonstrated a polymorphous infiltrate composed predominantly of S-100 protein and CD68 immunoreactive histiocytic cells.
  • He received chemotherapy with vinblastine, prednisone, 6-mercaptopurine and methotrexate and has been in remission for over 4 years.
  • Only one previous example of acute lymphoblastic leukemia in childhood has been reported with R-D disease.
  • [MeSH-major] Bone Marrow Transplantation / adverse effects. Graft vs Host Disease / etiology. Histiocytosis, Sinus / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adolescent. Antigens, CD. Antigens, Differentiation, Myelomonocytic. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Histiocytes. Humans. Male. Remission Induction. S100 Proteins

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Rosai-Dorfman disease.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18493991.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / S100 Proteins
  •  go-up   go-down


12. Hall RE, Agarwal S, Kestler DP: Induction of leukemia cell differentiation and apoptosis by recombinant P48, a modulin derived from Mycoplasma fermentans. Biochem Biophys Res Commun; 2000 Mar 5;269(1):284-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of leukemia cell differentiation and apoptosis by recombinant P48, a modulin derived from Mycoplasma fermentans.
  • P48 is a 48-kDa monocytic differentiation/activation factor which was originally identified in the conditioned medium of the Reh and other leukemia cell lines and has recently been shown to be a Mycoplasma fermentans gene product.
  • Previously, conditioned medium P48 has been shown to induce differentiation of HL-60 (human promyelocytic leukemia) cells.
  • We show that rP48-MBP induces differentiation of HL-60, U937 (human histiocytic lymphoma), and M1 (mouse myeloid leukemia) cell lines.
  • [MeSH-major] Apoptosis / drug effects. Bacterial Proteins / pharmacology. Cell Differentiation / drug effects. Cytokines / pharmacology. Leukemia / drug therapy. Leukemia / pathology. Membrane Proteins / pharmacology. Mycoplasma fermentans / chemistry

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10694514.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-58205; United States / NCI NIH HHS / CA / CA-72591
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Cytokines; 0 / Macrophage-1 Antigen; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; 0 / polypeptide 48
  •  go-up   go-down


13. Maruo T, Namikawa K, Kunihiro A, Lynch J, Shida T, Kishikawa S: Large granular lymphocytic leukaemia complicated with histiocytic sarcoma in a dog. J S Afr Vet Assoc; 2009 Dec;80(4):261-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large granular lymphocytic leukaemia complicated with histiocytic sarcoma in a dog.
  • Based on these findings this case was diagnosed as LGL leukaemia.
  • As a result of multiple-agent chemotherapy, the markedly elevated levels of lymphocytes gradually decreased to 7500/ml on day 122 and the patient maintained a good quality of life for the following 3 months.
  • The dog was diagnosed as having histiocytic sarcoma based on cytological and histological examination of the mass.
  • Shortly after diagnosis, the dog developed sudden onset of central nervous system signs and died on day 270.
  • However, this case was notable for complication with histiocytic sarcoma from another origin.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Histiocytic Sarcoma / veterinary. Leukemia, Large Granular Lymphocytic / veterinary
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Dog Diseases. Dogs. Fatal Outcome. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20458870.001).
  • [ISSN] 1019-9128
  • [Journal-full-title] Journal of the South African Veterinary Association
  • [ISO-abbreviation] J S Afr Vet Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] South Africa
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


14. Kaune KM, Baumgart M, Gesk S, Mitteldorf C, Baesecke J, Glass B, Haase D, Siebert R, Ghadimi BM, Neumann C, Emmert S: Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells. Arch Dermatol; 2008 Mar;144(3):361-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells.
  • BACKGROUND: An association of Sweet syndrome with chronic myeloid leukemia (CML) has been recently observed in patients treated with tyrosine kinase inhibitors.
  • After 10 months of taking nilotinib, he developed pneumonia with septic features.
  • Findings from histologic examination showed massive infiltrations of the whole dermis with neutrophil granulocytes as well as with monocytoid histiocytic cells.
  • Fluorescence in situ hybridization analysis of paraffin-embedded tissue revealed a BCR-ABL fusion, indicating the presence of t(9;22)(q34;q11).
  • The addition of oral prednisolone to an adequate antibiotic treatment led to rapid resolution of the cutaneous infiltrations.
  • CONCLUSIONS: Skin infiltrations consistent with Sweet syndrome can occur in patients with septic CML during the treatment with tyrosine kinase inhibitors, including nilotinib.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Protein Kinase Inhibitors / adverse effects. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / adverse effects. Sweet Syndrome / diagnosis

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347292.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


15. Matesic L, Locke JM, Bremner JB, Pyne SG, Skropeta D, Ranson M, Vine KL: N-phenethyl and N-naphthylmethyl isatins and analogues as in vitro cytotoxic agents. Bioorg Med Chem; 2008 Mar 15;16(6):3118-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Their activity against human monocyte-like histiocytic lymphoma (U937), leukemia (Jurkat), and breast carcinoma (MDA-MB-231) cell lines was assessed.
  • [MeSH-minor] Alkylation. Breast Neoplasms / drug therapy. Cell Line, Tumor. Female. Humans. Inhibitory Concentration 50. Leukemia / drug therapy. Lymphoma / drug therapy. Male. Structure-Activity Relationship

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182300.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 82X95S7M06 / Isatin
  •  go-up   go-down


16. Gupta SD, Gomes A, Debnath A, Saha A, Gomes A: Apoptosis induction in human leukemic cells by a novel protein Bengalin, isolated from Indian black scorpion venom: through mitochondrial pathway and inhibition of heat shock proteins. Chem Biol Interact; 2010 Jan 27;183(2):293-303
Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we have isolated and purified a novel protein named Bengalin (72kDa) from the venom, responsible for antiproliferative and apoptogenic activities against human leukemic cells U937 (histiocytic lymphoma) and K562 (chronic myelogenous leukemia).
  • Further insights revealed that Bax:Bcl2 ratio was elevated after Bengalin treatment.
  • [MeSH-minor] Amino Acid Sequence. Animals. Caspase 3 / metabolism. Caspase 9 / metabolism. Cytochromes c / metabolism. G1 Phase. HSP70 Heat-Shock Proteins / metabolism. HSP90 Heat-Shock Proteins / metabolism. Humans. India. K562 Cells. Leukemia / drug therapy. Membrane Potential, Mitochondrial / drug effects. Molecular Sequence Data. Poly(ADP-ribose) Polymerases / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. U937 Cells. bcl-2-Associated X Protein / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19913524.001).
  • [ISSN] 1872-7786
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / HSP70 Heat-Shock Proteins; 0 / HSP90 Heat-Shock Proteins; 0 / Heat-Shock Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Scorpion Venoms; 0 / bcl-2-Associated X Protein; 9007-43-6 / Cytochromes c; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9
  •  go-up   go-down


17. Choi YL, Park JH, Kim WS, Lee DY, Lee JH, Yang JM, Lee ES: Aggressive NK-cell leukaemia associated with reactive haemophagocytic syndrome. Clin Exp Dermatol; 2006 Jan;31(1):83-5
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive NK-cell leukaemia associated with reactive haemophagocytic syndrome.
  • We report a case of aggressive NK-cell leukaemia associated with reactive haemophagocytic syndrome in a 29-year-old Korean woman who had several small purpuric patches on both thighs.
  • The bone marrow examination showed diffuse histiocytic proliferation with several haemophagocytic macrophages, suggesting an associated reactive haemophagocytic syndrome.
  • Although we treated her with chemotherapy, she died 1 month later.
  • [MeSH-major] Killer Cells, Natural / immunology. Leukemia / immunology. Lymphohistiocytosis, Hemophagocytic / immunology. Lymphoma, T-Cell, Cutaneous / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309492.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


18. Blum R, Seymour JF, Hicks RJ: Role of 18FDG-positron emission tomography scanning in the management of histiocytosis. Leuk Lymphoma; 2002 Nov;43(11):2155-7
Genetic Alliance. consumer health - Histiocytosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of 18FDG-positron emission tomography scanning in the management of histiocytosis.
  • Diagnostic evaluation of histiocytic malignancies often involves a range of imaging studies to characterize skeletal and extraskeletal sites of involvement.
  • We report two cases where this modality was positive and facilitated therapeutic monitoring.
  • [MeSH-major] Fluorodeoxyglucose F18. Histiocytosis / radionuclide imaging. Tomography, Emission-Computed
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / diagnosis. Bone Neoplasms / drug therapy. Bone Neoplasms / radionuclide imaging. Disease Management. Histiocytosis, Langerhans-Cell / diagnosis. Histiocytosis, Langerhans-Cell / drug therapy. Histiocytosis, Langerhans-Cell / radionuclide imaging. Humans. Male. Neoplasm Staging / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12533041.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


19. Patel SK, Katz ER, Richardson R, Rimmer M, Kilian S: Cognitive and problem solving training in children with cancer: a pilot project. J Pediatr Hematol Oncol; 2009 Sep;31(9):670-7
MedlinePlus Health Information. consumer health - Memory.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Empirically validated interventions to address such disease and treatment related psychosocial morbidities are needed.
  • PROCEDURE: We conducted a pilot study to evaluate participants' acceptance and impact of a 15-session, clinic-based training program to teach compensatory learning and problem-solving skills in survivors with cognitive deficits.
  • [MeSH-major] Brain Neoplasms / psychology. Cognition Disorders / therapy. Learning Disorders / therapy. Leukemia / psychology. Memory Disorders / therapy. Problem Solving. Remedial Teaching. Survivors / psychology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Cranial Irradiation / adverse effects. Craniotomy / adverse effects. Female. Histiocytic Sarcoma / drug therapy. Humans. Infant. Male. Neuropsychological Tests. Parents / psychology. Patient Acceptance of Health Care. Patient Satisfaction. Pilot Projects. Postoperative Complications / psychology. Postoperative Complications / therapy


20. Dürken M, Finckenstein FG, Janka GE: Bone marrow transplantation in hemophagocytic lymphohistiocytosis. Leuk Lymphoma; 2001 Mar;41(1-2):89-95
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Familial hemophagocytic lymphohistiocytosis (FHLH) is a genetically heterogeneous autosomal recessive disease with histiocytic and lymphocytic infiltrations in multiple organs and is currently curable only by bone marrow transplantation (BMT).
  • Secondary HLH most commonly results from viral infections and some patients may be cured by treating the causative organism, others will need chemotherapy and immunosuppression.
  • Appropriate early treatment and a timely BMT will hopefully decrease mortality rates and improve neurodevelopmental outcome in this disease.
  • [MeSH-major] Bone Marrow Transplantation / mortality. Histiocytosis, Non-Langerhans-Cell / therapy

  • Genetic Alliance. consumer health - Hemophagocytic Lymphohistiocytosis (HLH).
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11342360.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 38
  •  go-up   go-down


21. Ferran M, Gallardo F, Salar A, Iglesias M, Barranco C, Pujol RM: Granulomatous dermatitis with enlarged histiocytes: a characteristic pattern of granulocyte colony-stimulating factor. Report of two cases and review of the literature. Dermatology; 2006;212(2):188-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two patients developed a pruritic maculopapular rash following treatment with granulocyte colony-stimulating factor (G-CSF).
  • Histopathological examination disclosed a superficial dermal inflammatory infiltrate composed of interstitially arranged large histiocytic CD68+ cells and perivascularly disposed lymphocytes.
  • This histopathological variant of granulomatous dermatitis with "enlarged histiocytes" seems to be characteristic of an unusual cutaneous reaction secondary to CSF treatment.
  • [MeSH-major] Drug Eruptions / pathology. Granulocyte Colony-Stimulating Factor / adverse effects. Granuloma / pathology. Histiocytes / pathology
  • [MeSH-minor] Acute Disease. Aged. Biopsy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Leukemia, Myeloid / drug therapy. Male. Middle Aged. Multiple Myeloma / drug therapy. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • (PMID = 16484826.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


22. Nishida S, Kikuichi S, Haga H, Yoshioka S, Tsubaki M, Fujii K, Irimajiri K: Apoptosis-inducing effect of a new bisphosphonate, YM529, on various hematopoietic tumor cell lines. Biol Pharm Bull; 2003 Jan;26(1):96-100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, YM529 was developed as a new third-generation bisphosphonate.
  • We found that YM529 inhibited cell proliferation in various hematopoietic tumor cell lines (acute promyelocytic leukemia cell line HL-60, chronic myeloid leukemia cell line K562, histiocytic lymphoma cell line U937, lymphoblastic leukemia T cell line Jurkat, acute lymphoblastic leukemia T cell line MOLT-4, lymphoblastic leukemia B cell line CCRF-SB) including myeloma (myeloma cell line HS-Sultan) dose-dependently and time-dependently to a degree equivalent or superior to that in myeloma, and induced apoptosis at a lower concentration as compared with YM175.
  • We confirmed many dead cells as well as apoptosis based on the detection of the nuclei with separate globular structure, the activation of caspase-3, and the decrease in mitochondrial transmembrane potential.
  • [MeSH-major] Apoptosis / drug effects. Diphosphonates / pharmacology. Hematologic Neoplasms / drug therapy. Imidazoles / pharmacology
  • [MeSH-minor] Cell Survival / drug effects. Cell Survival / physiology. HL-60 Cells. Humans. Intracellular Membranes / drug effects. Intracellular Membranes / physiology. Jurkat Cells. K562 Cells. Membrane Potentials / drug effects. Mitochondria / drug effects. Mitochondria / physiology. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / physiology. U937 Cells

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12520182.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Imidazoles; 127657-42-5 / YM 529
  •  go-up   go-down


23. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project: Stromal gene signatures in large-B-cell lymphomas. N Engl J Med; 2008 Nov 27;359(22):2313-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The addition of rituximab to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or R-CHOP, has significantly improved the survival of patients with diffuse large-B-cell lymphoma.
  • Whether gene-expression signatures correlate with survival after treatment of diffuse large-B-cell lymphoma is unclear.
  • The prognostically favorable stromal-1 signature reflected extracellular-matrix deposition and histiocytic infiltration.
  • CONCLUSIONS: Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment.
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols. Cyclophosphamide. Disease Progression. Doxorubicin. Extracellular Matrix / genetics. Gene Expression Regulation, Neoplastic. Genes, MHC Class II. Germinal Center. Humans. Immunologic Factors / administration & dosage. Kaplan-Meier Estimate. Middle Aged. Multivariate Analysis. Neovascularization, Pathologic / genetics. Prednisone. Prognosis. Rituximab. Vincristine


24. Hatakeyama S, Yoshino M, Eto K, Takahashi K, Ishihara J, Ono Y, Saito H, Kubodera N: Synthesis and preliminary biological evaluation of 20-epi-eldecalcitol [20-epi-1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D3: 20-epi-ED-71]. J Steroid Biochem Mol Biol; 2010 Jul;121(1-2):25-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eldecalcitol has potent biological effects on bone and is now in preparation for approval as a promising medicine for the treatment of osteoporosis in Japan.
  • In the induction of human myeloid leukemia cell (HL-60) differentiation, inhibition of the human histiocytic lymphoma cell (U937) proliferation, and increase in osteocalcin concentration in the human osteosarcoma cell (MG-63), 20-epi-eldecalcitol showed significantly enhanced activity compared to eldecalcitol.
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation. Chemistry, Pharmaceutical. Drug Design. Drug Evaluation, Preclinical. HL-60 Cells. Humans. Models, Chemical. Osteocalcin / chemistry. Osteoporosis / drug therapy. Receptors, Calcitriol / chemistry. Structure-Activity Relationship. U937 Cells

  • MedlinePlus Health Information. consumer health - Vitamin D.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20304058.001).
  • [ISSN] 1879-1220
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Calcitriol; 0 / eldecalcitol; 104121-92-8 / 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3; 104982-03-8 / Osteocalcin; 1406-16-2 / Vitamin D; FXC9231JVH / Calcitriol
  •  go-up   go-down


25. Requena L, Kutzner H, Palmedo G, Pascual M, Fernández-Herrera J, Fraga J, García-Díez A, Yus ES: Histiocytoid Sweet syndrome: a dermal infiltration of immature neutrophilic granulocytes. Arch Dermatol; 2005 Jul;141(7):834-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Immunohistochemical studies demonstrated that most cells of the infiltrate showed immunoreactivity for CD15, CD43, CD45, CD68, MAC-386, HAM56, and lysozyme, which is consistent with a monocytic-histiocytic immunoprofile.
  • However, intense myeloperoxidase reactivity was detected in most of the cells with histiocytic appearance, which raised the possibility of specific cutaneous involvement by myelogenous leukemia.
  • We named this histopathologic variant histiocytoid Sweet syndrome, which should not be mistaken with leukemia cutis or other inflammatory dermatoses that are histopathologically characterized by histiocytes interstitially arranged between collagen bundles of the dermis.
  • [MeSH-major] Diclofenac / analogs & derivatives. Histiocytes / pathology. Sweet Syndrome / drug therapy. Sweet Syndrome / pathology
  • [MeSH-minor] Acetaminophen / administration & dosage. Administration, Oral. Adult. Aged. Biopsy, Needle. Cohort Studies. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prednisone / administration & dosage. Severity of Illness Index. Treatment Outcome

  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. PREDNISONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Dermatol. 2014 Feb;53(2):e80-2 [23330976.001]
  • [CommentIn] Arch Dermatol. 2005 Jul;141(7):893-5 [16027307.001]
  • (PMID = 16027297.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 144O8QL0L1 / Diclofenac; 362O9ITL9D / Acetaminophen; RPK779R03H / aceclofenac; VB0R961HZT / Prednisone
  •  go-up   go-down


26. Feldman AL, Minniti C, Santi M, Downing JR, Raffeld M, Jaffe ES: Histiocytic sarcoma after acute lymphoblastic leukaemia: a common clonal origin. Lancet Oncol; 2004 Apr;5(4):248-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histiocytic sarcoma after acute lymphoblastic leukaemia: a common clonal origin.
  • [MeSH-major] Gene Rearrangement. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Sarcoma / etiology. Sarcoma / genetics
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clone Cells. DNA, Neoplasm / genetics. Humans. Male

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15050956.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


27. Dalle JH, Leblond P, Decouvelaere A, Yakoub-Agha I, Preudhomme C, Nelken B, Mazingue F: Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow transplantation for T-ALL. Leukemia; 2003 Oct;17(10):2056-7
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow transplantation for T-ALL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Marrow Transplantation / adverse effects. Leukemia-Lymphoma, Adult T-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasms, Second Primary / drug therapy. Sarcoma / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Child, Preschool. Humans. Male. Treatment Outcome






Advertisement